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Abstract
Background: Stage I non-small cell lung cancer (NSCLC) is potentially curable, and surgery is considered to be the
standard of care for patients with good performance status and minimal co-morbidity. However, a significant
proportion of patients with stage I NSCLC have a poorer performance status and significant medical co-morbidity that
make them at higher risk of morbidity and mortality from surgery.
Stereotactic ablative radiotherapy (SABR), which uses modern radiotherapeutic techniques to deliver large doses of
radiation, has shown superiority over conventional radiotherapy in terms of local control and toxicity and is a standard
of care for patients with stage I NSCLC who are at too high risk for surgery. However, it is not known whether surgery
or SABR is the most effective in patients with stage I NSCLC who are suitable for surgery but are less fit and at higher
risk surgical complications. Previous randomised studies have failed to recruit in this setting, and therefore, a feasibility
study is required to see whether a full randomised control trial would be possible.
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Methods/design: SABRTooth is a UK-based, multi-centre, open-label, two-group individually (1:1) randomised
controlled feasibility study in patients with peripheral stage I NSCLC considered to be at higher risk from surgical
resection. The study will assess the feasibility of conducting a definitive large-scale phase III trial. The primary objective
is to assess recruitment rates to provide evidence that, when scaled up, recruitment to a large phase III trial would be
possible; the target recruitment being 54 patients in total, over a 21-month period. There are multiple secondary and
exploratory objectives designed to explore the optimum recruitment and data collection strategies to help optimise
the design of a future phase III trial.
Discussion: To know whether SABR is a better, equivalent or inferior alternative to surgery for higher risk patients is a
key question in lung cancer. Other studies comparing SABR to surgery have closed early due to poor recruitment, and
therefore, the SABRTooth feasibility study has been designed around the UK National Health Service (NHS) cancer
pathway incorporating many design features in order to maximise recruitment for a future definitive phase III trial.
Trial registration: controlled-trials.com ISRCTN13029788
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Background
Non-small cell lung cancer (NSCLC)
Stage I NSCLC is potentially curable, and surgery is con-
sidered the standard of care for patients with good per-
formance status and minimal co-morbidity, with 5-year
overall survival (OS) of around 60 % [1]. However, a sig-
nificant proportion of patients with stage I NSCLC are
not suitable for surgery because of poor fitness, often re-
lated to the presence of significant medical co-morbidities
including chronic obstructive pulmonary disease (COPD)
and cardiovascular disease. For instance, the National
Lung Cancer Audit (NLCA) database of lung cancer treat-
ment in England and Wales from 2008 to 2012 showed
that the resection rate for patients with histologically
confirmed NSCLC was 20.8 and 21.4 % in those patients
aged <65 and 65–74, respectively; for patients aged >75,
the rate was 13.9 % [2]. An analysis of the same database
shows that 30- and 90-day mortality following surgery
rise steeply with age [3]; 90-day mortality being 6.4 %
for 70-year-olds versus 43 % for 80-year-olds, a deterior-
ating performance status is also a factor influencing the
outcome [4].
An alternative, potentially curative, treatment to sur-
gery is conventionally fractionated radical radiotherapy
[5]. However, the results of conventional fractionated
radical radiotherapy (using 20–33 fractions of radiation
at a daily dose of 2–2.75 Gy to a total dose of 55–66 Gy)
are poor. A meta-analysis reported OS at 2- and 5-year
rates of 52 and 19 % [6], respectively, with a mean local
recurrence rate of 40 % [7]. Though the CHART trial of
hyper-fractionated radiotherapy and modelling studies
have shown a steep dose–response curve for local con-
trol of NSCLC [4, 8], a trial comparing 60 with 74 Gy,
albeit combined with concurrent chemotherapy, was
stopped due to increased mortality in the high-dose arm.
Thus, 60–66 Gy in 2 Gy per fraction has been the
standard of care for NSCLC in many countries; in the
UK, a hypofractionated regime of 55 Gy in 20 fractions
is also used. Concerns regarding toxicity often preclude
patients with significant co-morbidity from being offered
conventionally fractionated radical radiotherapy. How-
ever, stereotactic ablative radiotherapy (SABR) or stereo-
tactic body radiotherapy (SBRT), which uses modern
radiotherapeutic techniques to deliver large doses of ra-
diation in 3–8 fractions to a total in excess of 100 Gy
biologically equivalent dose (BED), has shown superior-
ity (albeit in uncontrolled series) to conventional radio-
therapy in terms of local control and toxicity [6, 7].
SABR is highly accurate in its delivery and con-
formal with the irradiated volume (planning treatment
volume—PTV); consisting of an individually deter-
mined margin for tumour movement, a very small
margin added for daily set-up error as image guidance
is used during the treatment and with no margin ap-
plied for microscopic spread. Thus, the proportion of
normal lung irradiated to significant dose is much lower
for SABR compared with conventionally fractionated rad-
ical radiotherapy.
Hence, SABR is a low-risk treatment in the majority of
patients, even those with severe pulmonary morbidity
(excluding those with interstitial pulmonary fibrosis). A
meta-analysis has shown a 5-year survival of 42 % [6]
and local recurrence of less than 10 % [7]. A study of
the treatment of early stage NSCLC in a large region of
the Netherlands showed that as SABR was introduced,
the proportion of patients offered no specific anti-cancer
treatment fell; those offered radical radiotherapy rose
without affecting the number of patients receiving sur-
gery, accompanied by an improvement in OS for early
stage NSCLC [9]. These data strongly imply that SABR
is a good option for the majority of patients with medic-
ally inoperable NSCLC.
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Patient population
A meta-analysis compared SABR with surgery in cohorts
of patients, with adjustment for age and medical oper-
ability, and found similar outcomes for mortality and
tumour control [10]. However, no adequately powered
randomised trial comparing the two modalities has been
successful.
Worldwide, there have been three trials comparing
surgery and SABR: ROSEL (NCT00687986), STARS
(NCT00840749) and ACOSOG–RTOG (NCT01336894),
all of which closed early due to failure to recruit. In
ROSEL, this was thought to be due to lack of support
from the surgical community as it included medically
operable patients [11]. The STARS trial was also limited
to patients fit for conventional surgery (lobectomy or
pneumonectomy), whilst the RTOG trial was limited to
patients at high risk of lobectomy, where the planned
surgery was sub-lobar (wedge or segmental) resection.
An intention-to-treat pooled analysis of the ROSEL and
STARS trial was recently published. In the STARS trial,
of the 234 patients screened, only 36 were enrolled and
randomly assigned and only 22 patients were enrolled
into the ROSEL study [12]. The results of this ana-
lysis have shown an overall advantage, in terms of 3-
year survival, for SABR; however, because of the
limited power of the study, this result cannot be con-
sidered definitive.
Previously, the only randomised trial of surgery versus
radiotherapy for NSCLC recruited 58 patients from 1954
to 1958 and was published in 1963; this showed a 4-year
survival for surgery of 23 versus 7 % for radiotherapy, al-
though the difference was not statistically significant
[13]. Therefore, bearing in mind the difficulty of carrying
out a randomised trial of surgery versus radiotherapy, a
multidisciplinary group was established to produce the
protocol for the SABRTooth trial. This multidisciplinary
group designed the protocol around the well-established
referral pathway for cancer patients in the UK where all
cancer patients’ cases are discussed in a multidisciplinary
team (MDT) meeting before a treatment decision is
made. At least one representative of all clinical special-
ities (pathologists, surgeons, chest physicians, oncolo-
gists, cancer nurses and radiologists) involved in lung
cancer diagnosis and management is present to provide
a balanced treatment decision.
The aim was to produce a pragmatic protocol based
on everyday practice such that SABR could be delivered
using any approved technique, and the choice of surgical
procedure (lobectomy, anatomical segmentectomy or
wedge resection) was left to the discretion of the treating
thoracic surgeon.
Subsequently, a small number of established lung can-
cer centres and their referral units were chosen for this
feasibility trial with a trial workshop and launch meeting
to help get “buy-in” from surgeons, respiratory physi-
cians and oncologists from each centre.
Methods/design
Trial aims and objectives
The SABRTooth trial aims to determine the feasibility
and acceptability of conducting an adequately powered
definitive phase III randomised controlled trial (RCT)
comparing surgery with SABR in patients with periph-
eral stage I NSCLC deemed at higher risk of complica-
tions from surgical resection.
Trial design
SABRTooth is a UK-based, multi-centre, open-label, two-
group individually randomised controlled feasibility study
targeted at patients with peripheral stage I NSCLC consid-
ered at higher risk from surgical resection. Patients will be
randomised (1:1) to either SABR or surgical resection
(Fig. 1). Due to the different treatment modalities, it is
not possible to blind patients or clinicians to treat-
ment allocation.
Patient and public involvement (PPI)
Given the known difficulties in recruiting patients to
RCTs where the two treatment options are very difficult,
PPI has been critical in the development of the trial. We
have had patient and patient’s relatives input into the
protocol design, lay summary patient information leaf-
lets and held an initial trial workshop and trial launch
meeting. In addition, we have two PPI members on the
trial management group (TMG) and a further PPI mem-
ber on the trial steering committee (TSC).
Trial population
Those patients considered at higher risk of complica-
tions from surgical resection are defined as “a level of
fitness that could lead to a greater than average morbid-
ity or mortality from surgery”. This includes those pa-
tients with poor lung function who are at risk of
increased post-operative dyspnoea that would be suffi-
cient to be unacceptable to them (this is subjective and
will vary from patient to patient) and patients who have
an increased risk of cardiovascular morbidity that might
lead to a perioperative complication or death.
In order to maximise recruitment, the protocol does not
specify what constitutes high risk but leaves it to the judg-
ment of the individual MDT. However, we have produced
guidelines (Fig. 1: SABRTooth trial schema; Table 1) to en-
sure appropriate patients are considered for the trial. We
also intend to collect data on the number of patients con-
sidered for the trial but not invited to enter because their
risk is deemed too high or within acceptable limits for sur-
gery, along with the reason(s) for why they were not con-
sidered suitable.
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Patient is invited to take 
part in Qualitative 
Feedback Interviews
Patient declines
Eligibility
• Peripheral (>2 cm from the main airways), Stage I (T1a/1b, 
T2a, N0M0 < 5cm), NSCLC
• Lung cancer MDT consensus is the patient is suitable for 
surgery but at higher risk of complications
Randomised at baseline (N = 54)
1:1 stratified by trial site only
Reviewed at MDT meeting and identified as potentially eligible 
Follow-up visits at 6 weeks, 3, 6, 9, 12, 18 & 24 months post-
treatment or until the end of follow-up period (6 months after
last participant randomised). Minimal clinical data and patient
reported questionnaire data also collected at 15m and 21m
post-treatment and OS data collected at the end of the trial via
the NCDR.
Patient consents
Patient or clinician 
decides against 
randomised treatment 
Seen by Surgeon
Surgery (N = 27) SABR (N = 27)
Seen by Clinical Oncologist
Consent with Research Nurse or Respiratory Physician
Seen by Respiratory Physician for diagnosis. SABRTooth 
discussed and information sheet provided
Fig. 1 SABRTooth trial schema
Table 1 Guidance for definition of higher risk from surgical complications
Group A
Suitable for surgery—but at higher risk of
complications compared to group B
(potentially eligible for SABRTooth)
▪ CPEX—VO2 max 10–15 L/kg/min
▪ ISWT—walk 250–400 m
▪ Mortality risk from Nottingham score: 6–20 % at 90 days
The patient can be approached
for the trial if they meet one or
more of these criteria
Group B
Suitable for surgery—lower risk of complications ▪ CPEX—VO2 max >15 L/kg/min, anaerobic threshold
▪ ISWT—walk >400 m and without significant desaturation
▪ Predicted post-operative FEV1 > 50 %
▪ Mortality risk from Nottingham score <6 % at 90 days for
lobectomy (it is not anticipated that patients will need a
pneumonectomy in this group of peripheral cancers).
Not suitable for the trial
Group C
Unsuitable for surgery as predicted risk
of complications is too high
▪ CPEX—VO2 max <10 L/kg/min
▪ ISWT—walk <250 m and significant desaturation
▪ Pre-operative FEV1 < 30 %
▪ Mortality risk from Nottingham score >20 % at 90 days for
lobectomy (it is not anticipated that patients will need a
pneumonectomy in this group of peripheral cancers).
▪ Reduced ejection fraction (e.g. <40 %) or evidence of ongoing
myocardial ischemia
▪ Recent cerebrovascular event (e.g. within 3 months of
planned surgery)
Not suitable for the trial
We have suggested the above criteria for all groups to assist patient selection. However, as there are other individual contributing factors, the final decision on
whether the patient is suitable for the trial will rest with the local MDT
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Overall primary objectives
 To quantitatively assess the recruitment rate in
order to provide evidence that when recruitment
rates are scaled up, recruitment to a large phase III
trial would be possible
There will be a 21-month recruitment period. In order
to demonstrate that recruitment, targets for the planned
phase III trial can be met within an adequate timeframe;
a “steady state” of recruitment must be observed. Formal
monitoring of recruitment will begin 6 months after the
start of recruitment (allowing a run-in period for set-
up), where an average of three patients per month must
be randomised over the remaining recruitment period in
order to demonstrate a “steady state” of recruitment.
Secondary objectives
 To quantitatively assess uptake of allocated
treatment arm (surgery/SABR) as a measure of
acceptability of the trial and appropriateness of
patients recruited
 To determine the number of patients screened and
identified as eligible per month, to provide evidence
of appropriate numbers of patients, to meet the
sample size requirements of a future phase III trial
 To explore reasons for non-participation of eligible
patients and participants not undergoing their
allocated treatment procedure
 To assess the feasibility of collecting the quality of
life (QoL) data and determine the optimal frequency
of data collection for the planned phase III trial,
specifically for the Euro-Quality of Life 5D utility
score (EQ-5D) and Euro-Quality of Life visual
analogue scale (EQ-VAS), Cancer Quality of Life
Questionnaire (QLQ-C30), Lung Cancer-Specific
Quality of Life Questionnaire (QLQ-LC13) and a
medical resource use and societal–economic
questionnaire
 To obtain EQ-5D utility estimates to inform the
sample size calculations for the phase III trial
Exploratory objectives
 To qualitatively explore in a cohort of patients
acceptability of the trial (i.e. reason for trial non-
participation and participant refusal of allocated
treatment) to assist in optimisation of recruitment
strategies employed for a future definitive phase III
trial
 To explore participant recruitment pathways at both
treatment centres and referral units in order to assist
in recruitment strategy planning for a future study
 To explore the use of newly available tools
(Nottingham risk score) in defining patients at a
higher risk from surgical resection across the six
trial sites in order to assist in optimising recruitment
for a future study
 To monitor the 30-/90-/180-day mortality rates
overall and in both treatment arms (surgery/SABR)
and overall survival (OS) at the end of the study
Sample size
As the study is designed to assess the feasibility of con-
ducting a definitive large-scale phase III trial, a formal
power calculation is not considered appropriate as ef-
fectiveness is not being evaluated.
For this feasibility study, we plan to recruit 54 patients
in total (i.e. 27 to each treatment arm) from six UK hos-
pitals, four tertiary treatment centres and two smaller re-
ferral units, over a 21-month recruitment period.
Achieving the recruitment targets within the feasibility
study will help demonstrate that, when recruitment rates
are scaled up, recruitment into a large-scale phase III trial
is feasible. It has been estimated that 690 patients are re-
quired for the phase III trial to have 80 % power to show
non-inferiority (NI) of SABR to surgery, where this is de-
fined as SABR being less than 8 % worse in terms of 3-
year OS (derived from an in-house simulation programme
which accounts for the likely excess early death rate in the
surgery arm in comparison with the SABR arm). This
sample size also yields >97 % power for a similar 10 % NI
margin for difference in mean quality-adjusted life years
(QALYs) per arm and greater than 80 % power to show
superiority.
In order to demonstrate the feasibility of recruitment
within this feasibility study, we are aiming to recruit on
average three patients per month from four UK large
treatment centres and two smaller referral units. This
equates to 36 patients per year (i.e. 9 patients from each
of the 4 large treatment centres). Including these 4
established centres (and their referral units) within a
subsequent phase III trial, recruiting at the same rate,
180 patients could be recruited over a 5-year period. We
would also aim to include an additional 15 UK large
treatment centres, plus their associated referral units. If
these 15 centres recruited at 75 % of the rate of the cen-
tres within the feasibility study, an additional 100 patients
could be recruited a year; 500 patients over a 5-year
period. Thus, with approximately 19 large treatment cen-
tres and their associated referral units, a target of 690 pa-
tients over a 5-year period would be feasible, which
equates to a rate of 138 patients per year.
Additionally, a number of international groups includ-
ing Australia (TROG) and Europe have confirmed interest
in the study and are keen to be involved. International col-
laboration for the phase III trial would increase the trial
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population considerably and reduce the recruitment
period significantly.
Recruitment
SABRTooth opened to recruitment in July 2015.
The recruitment period is 21 months, and all partici-
pants will be followed up until 6 months after the last
patient has been randomised. Participants will be re-
cruited from six UK hospitals in total, a mixture of ter-
tiary treatment centres and smaller referral units. All
treatment centres are established lung cancer surgical
centres with established SABR programmes for lung
cancer and a proven track record of recruitment into
clinical trials.
We recognise the challenge of avoiding clinician bias
and the need to describe equipoise between the two very
different treatment interventions. To address this, the re-
spiratory physician and research nurse will introduce the
trial to avoid any bias. We have assessed existing evidence
in optimising recruitment to trials and held mock patient
interview scenarios and used these as a basis to develop a
training guide for recruiters on how best to approach and
discuss the trial with patients [14, 15]. A careful explan-
ation of the risks and benefits of the two treatment inter-
ventions is crucial; such risks will be clearly explained to
interested patients in an unbiased and fair way, assisted by
written trial-specific patient information. Potential pa-
tients for this study will be identified by expert lung can-
cer teams through the appropriate MDT meeting.
Randomisation
Following confirmation of written informed consent and
eligibility, patients will be randomised using a 24-hour
telephone or web-based system based at the Leeds Insti-
tute of Clinical Trials Research (Leeds, UK). Patients will
be randomised using stratified permuted blocks to either
surgery or SABR (1:1), stratified for recruiting site only.
Patient randomisation is to take place as close to the
intervention start date as possible and, in line with
National Health Service (NHS) guidelines, is aimed to
be done no more than 31 days prior to treatment start
date.
Pre-treatment investigations
Patients must have had a pathological and/or clinical
and radiological diagnosis of stage I NSCLC. Patho-
logical confirmation prior to randomisation is encour-
aged, but patients without histology, providing the
putative tumour has demonstrated growth on serial
radiological imaging (preferably, on CT, but if the lesion
is clearly evaluable on chest X-ray, this will be accept-
able) and is positron emission tomography (PET) avid
(showing FDG avidity greater than the mediastinal blood
pool), will be eligible (Table 2).
The following tests are required to determine eligibility:
 History and examination
 Full body PET-CT (within 8 weeks prior to
randomisation)
 Pregnancy test (if woman of childbearing potential)
 Assessment of Eastern Cooperative Oncology Group
performance status (ECOG PS), weight, MRC
dyspnoea score, Charlson co-morbidity index [16]
 Pulmonary function tests (FEV1, FVC, KCO and
DLCO/VA)
 Calculated predicted post-resection lung function
 FBC and serum biochemistry (FBC U+E, LFT, calcium)
 ECG
 Cardio-pulmonary exercise testing (CPEX) and/or
Incremental Shuttle Walk Test (ISWT)
 Thoracoscore, calculated global risk score [17]
 Nottingham risk score [3]
The following investigations and assessments may be
carried out prior to randomisation, if clinically indicated:
 Cardiac tripartite risk assessment
Table 2 SABRTooth trial inclusion and exclusion criteria
Inclusion criteria
1. Histological and/or clinical and radiological diagnosis of NSCLC
2. Primary tumour characteristics
i. Peripherally located tumour as defined in the RTOG 0236 and UK
SABR consortium guidelines. This states that the tumour must be
more than 2 cm in axial diameter from a major airway = “No Fly
Zone”. This includes the trachea, carina, right and left main
bronchus and extends to the bifurcation of the right upper, right
middle, right lower, left upper and left lower lobe bronchioles.
Maximal axial diameter ≤5 cm measured on lung windows on
computed tomography (CT).
3. No evidence of hilar or mediastinal lymph node involvement. Any
hilar or mediastinal lymph nodes that are either PET positive or
>1 cm in short diameter must be sampled by endo-bronchial
ultrasound or oesophageal endoscopic ultrasound or mediastinoscopy
and demonstrate negative cytology and/or pathology.
4. The local lung cancer MDT is of the opinion that a patient is
considered suitable for either surgical resection or SABR treatment
AND also to be at higher risk complications from surgical resection.
5. Age ≥18
6. Female patients must satisfy the investigator that they are not of
childbearing potential or not pregnant (i.e. be willing to undergo a
pregnancy test within 72 hours of surgery or day 1 of SABR) or are
not of childbearing potential.
7. Able and willing to provide written informed consent
Exclusion criteria
1. Previous radiotherapy within the planned treatment volume
2. History of clinically significant diffuse interstitial lung disease
3. Any history of concurrent or previous invasive malignancy that in the
opinion of the investigator could impact on trial outcomes
4. Clinical or radiological evidence of metastatic spread
5. History of psychiatric or addictive disorder, or other medical condition
that, in the opinion of the investigator, would preclude the patient
from meeting the trial requirement.
6. Previous systemic therapies, including targeted and experimental
treatments, for their current lung cancer diagnosis
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 Cardiology review if the patient has an active
cardiac condition, ≥3 risk factors or poor cardiac
functional capacity
 Split lung function testing can be used if a
ventilation or perfusion mismatch is suspected
Follow-up
The planned duration of the trial follow-up is until
6 months after the last participant is randomised.
Follow-up frequency will be in line with current NHS
practice with routine follow-up visits and data collection
at 6 weeks, 3, 6, 9, 12, 18 and 24 months post-treatment.
Minimal clinical data will also be recorded at 15 and
21 months post-treatment; patient-reported question-
naires due to be completed at these time points will be
administered via post. OS data will be captured again at
the end of the study for all participants via the National
Cancer Data Repository (NCDR) (Fig. 1).
Data collected at follow-up will include the following:
 Post-operative/post-SABR complications and
severity
 Further anti-cancer therapy
 Patient status (alive or dead)
 ECOG PS, weight, MRC dyspnoea scale score
 Details of any local or distant recurrence,
including date and site of recurrence and method
of diagnosis
 Details of any new primary cancer diagnoses
including date and site of recurrence and method of
diagnosis
Follow-up imaging by CT scan will be performed as
per local practice, and it is anticipated that this will be at
6, 12 and 24 months post-treatment. Other imaging is
not mandated and should be performed as clinically
indicated.
Trial organisation and administration
The SABRTooth trial is funded by the National Institute
for Health Research (NIHR), Research for Patient Benefit
(RfPB) Programme (PB-PG-0613-31114), and is spon-
sored by Leeds Teaching Hospitals NHS Trust.
Trial supervision will be established according to the
principles of Good Clinical Practice (GCP) and in line
with the relevant Research Governance Framework within
the UK and through adherence with CTRU standard oper-
ating procedures (SOP). A core internal project team,
TMG and TSC will be established, with the TSC perform-
ing a dual role and acting as the data monitoring and
ethics committee (DMEC). Overall data and trial manage-
ment will be provided by the Clinical Trials Research Unit
(CTRU) (University of Leeds, UK).
Qualitative interviews
The trial includes embedded qualitative exploration of
the reasons for non-participation in the SABRTooth
study. As the two treatments are very different, patients
may have a strong preference for either surgery or SABR
or may feel uncomfortable to have a decision between
such different treatment options being taken out of their
hands. What patients understand, perceive and feel
about how the SABRTooth study and how it was pre-
sented to them and their expectations of study burden
will be explored in qualitative feedback interviews. Par-
ticipants who agree to participate in the study but subse-
quently do not take up their treatment allocation after
being randomised will also be invited to take part in a
feedback interview (Fig. 1). Understanding why patients
choose not to participate or do not take up their treatment
allocation will be crucial in assisting optimal recruitment
methods and ensuring the most appropriate design of any
subsequent phase III study.
Quality of life
Participants will be asked to complete questionnaires at
baseline, day 1 of treatment, 6 weeks post-treatment and
then 3 monthly until 24 months post-treatment or until
the end of the trial follow-up period (6 months after the
last patient has been randomised). Questionnaires to be
completed include the following:
 EQ-5D™ and EQ-VAS™
 EORTC QLQ-C30 and QLQ-LC13 (not collected at
15- and 21-month time points)
 Baseline and follow-up resource use and societal–
economic questionnaires
Questionnaires will be completed by participants at
their standard clinic visits, i.e. baseline; day 1 of treat-
ment; 6 weeks post-treatment; and 3, 6, 9, 12, 18 and
24 months post-treatment. Questionnaires due to be
completed at 15 and 21 months post-treatment will be
administered via post.
The frequent collection of quality of life (QoL) data
within this feasibility study is necessary in order to as-
sess the burden to patients. This will be assessed by
monitoring compliance rates in terms of proportion of
questionnaires returned and completed and will inform
the optimal frequency of data collection for the planned
subsequent phase III trial. Averaged QALYs are intended
as a co-primary endpoint for the planned phase III trial,
as such, determining the optimal frequency of EQ-5D
data collection within this feasibility study is crucial.
Utility estimates will be derived from the EQ-5D data
collected within this feasibility study and used to in-
form the power calculations for the QALY co-primary
endpoint.
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Health economics
As this is a feasibility study, a formal cost analysis or
cost-effectiveness analysis will not be performed. The re-
source use and societal–economic data will be analysed
and reported using descriptive statistics of frequency
and quantity of specific resources used on average by pa-
tients. The objective will be to identify the main drivers
of difference in resource use and out-of-pocket expenses
between the two arms. Compliance and missing data will
also be described. These data will inform an efficient de-
sign of the patient questionnaires in the subsequent
phase III study.
Statistical methods and analysis
Statistical analysis will be the responsibility of the SABR-
Tooth CTRU trial statistician. A full statistical analysis
plan will be written before any formal analyses are
undertaken. As this is a feasibility study looking at re-
cruitment potential, the analysis will be performed
through descriptive statistics rather than formal hypoth-
esis testing.
The analysis of the primary endpoint and all secondary
endpoints relating to recruitment and withdrawals from
the trial will take place at the end of the 21-month re-
cruitment period. Final analysis of all other endpoint
data will be carried out 6 months after the final partici-
pant has been randomised.
The primary endpoint analysis will be based on the
population of participants recruited within the formal
monitoring period. All further analysis will be carried
out on the intention-to-treat (ITT) population defined
as all participants randomised to the trial, regardless of
adherence to the protocol, withdrawal of consent or
losses to follow-up. Participants will be included within
the treatment arm to which they were randomised.
An interim analysis will take place approximately mid-
way through the study and be reported to the TSC. The
aim of the interim analysis is to evaluate and monitor
the key study objectives (i.e. recruitment rates, number
of participants taking up their treatment allocation, feed-
back from the qualitative interviews), as well as expected
serious complications (SCs) and unexpected serious
complications (USCs) and the delivery time of surgery/
SABR post-randomisation. The TSC will have the oppor-
tunity to raise any concerns with the trial progression/
running allowing the trial team to improve processes go-
ing forward.
Primary endpoint analysis
 Recruitment rates over the whole 21-month
recruitment period will be reported overall and by
recruiting site. The average recruitment rate per
month and in total over the formal monitoring
period will be reported in order to evaluate the
primary objective of the study.
Secondary endpoint analysis
 The total number of patients considered for the trial
and assessed as being eligible will be reported by
recruiting site along with reasons for non-
randomisation.
 The proportion of participants undergoing their
allocated treatment procedure (surgery/SABR) will
be summarised overall, by treatment arm and by
recruiting site, along with reasons for non-
compliance.
 The proportion of QoL questionnaires returned and
completed at each data collection timepoint will be
reported overall, by treatment arm and by recruiting
site. EQ-5D utility scores and standard deviations
will be derived for each participant in line with the
EQ-5D user guide. Average utility scores over
follow-up will be presented for each treatment arm
and overall and used to inform the sample size
calculations for the planned phase III trial.
Exploratory data analysis
 The feedback interviews will be professionally
transcribed verbatim and managed with help of
NVivo. The data will be analysed using inductive
thematic analysis [18, 19]. The analysis will be
further refined by using a constant comparison and
contrastive approach and looking for negative cases
in order to examine for similarities and differences
within and between the patients in different sites
and within and between patient groups.
 Descriptive summaries of the participant
recruitment pathways at the individual sites and site
criteria for identifying patients at a higher risk from
surgical resection will be reported. Intended
pathways and criteria used at the start of
recruitment and subsequent changes during
recruitment will be described.
 The 30-, 90- and 180-day mortality rates overall and
in each treatment arm (measured post-treatment)
will be summarised, and 95 % confidence intervals
will be constructed. Given that these rates will be
based on a limited sample, they will be treated as
exploratory and used only to compare with recent
figures in the literature rather than influence the
sample size for the planned phase III trial.
 OS rates as obtained via the NCDR will be
reported but an analysis formally comparing the
two treatment arms will not be performed due to
the lack of power within this feasibility study. By
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collecting OS data on all participants within this
study, this may then be used in conjunction with
the OS data generated from the planned phase III
trial in a formal meta-analysis which will add to
the overall evidence base for these two
interventions.
 Rates of related complications, serious complications
and unexpected serious compliances will be reported
by treatment arm and overall, along with the
average and range of delivery times of surgery and
SABR post-randomisation.
Discussion
To know whether SABR is a better, equivalent or inferior
alternative to surgery for higher risk patients is a key
question in lung cancer. The primary aim of this feasibil-
ity study is to demonstrate that, over 21 months, enough
patients can be randomised from 6 centres to indicate
that a phase III trial recruiting 690 patients over
5 years in 20 UK centres would be feasible. The mul-
tiple secondary and exploratory endpoints will help
determine the most optimum recruitment and data
collection strategies and help optimise the design of a
future phase III trial where the key aims would be to
show NI of SABR to surgery and determine the rela-
tive costs of the two treatments and their effects on
quality of life. Other studies comparing SABR to sur-
gery have closed early due to poor recruitment, and
therefore, the SABRTooth trial is a pragmatic study
based on everyday practice in hospitals managing lung
cancer. Considerable effort has been made to try and
maximise recruitment.
 The SABRTooth feasibility study has been designed
around the UK NHS cancer pathway for managing
lung cancer.
 Neither histological proof nor exact quantitative
measurement of risk for surgery is mandated for
entry into the trial.
 The protocol has been developed through
national lung cancer meetings over the past
3–4 years to promote awareness to the UK
clinical oncologists, respiratory physicians and
thoracic surgeons.
 A strong MDT with representatives of all concerned
medical specialities involved in the management of
lung cancer has developed the protocol.
 A small number of centres with highly motivated
clinicians have been selected.
 PPI has been critical to the development of the
protocol, lay summary and patient information
leaflets.
 Mock patient interview scenarios with constructive
feedback have been produced to provide a guide
on how to approach and discuss the trial with
patients.
 The trial is introduced to patients by a “neutral”
respiratory physician and then, if the patient is
interested in the study, consent is obtained by a lung
cancer trials nurse.
 Approached patients who decline randomisation or
their allocated treatment arm are offered an
interview to explore their reasons for not entering
the trial. Lessons learnt can then be used to try and
improve recruitment.
Therefore, we believe that such a well-designed
feasibility study in this clinical scenario will address
very important issues of clinician and patient equi-
poise. We hope that, if this study is successful, we will
be able to progress to a national randomised phase III
study.
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